Yinapu Completes Tens of Millions RMB Series A Funding Round to Advance Its Proprietary Nanochip-Based Mass Spectrometry Diagnostic Platform

VCBeat has learned that Zhejiang Enaspec Life Technology Co., Ltd. (hereinafter referred to as “Enaspec”) recently announced the completion of its tens-of-millions-yuan Series A financing round. The round was led by Wosheng Capital, with participation from Shicui Capital, Shanghai Ruikang Biotechnology, and other institutional and strategic investors.

Yinapu is a mass spectrometry detection enterprise centered on its proprietary nanochip analysis system. Led by Professor Qian Kun, a Changjiang Scholar, the team comprises numerous high-level overseas talents and senior industry experts. By integrating its independently designed and developed nanochips with artificial intelligence, the company has established a molecular omics engineering platform for major diseases and the “Intelligent Mass Spectrometry Medical Detection and Analysis Platform (iMS-Clinics)” system. Targeting large-scale population cohorts, it has successfully achieved high-throughput, rapid screening and identification of metabolic biomarkers in trace body fluid samples, thereby realizing the clinical translation and application of novel biomarkers and their combinations.

The proceeds from Yinapu’s current financing round will be primarily allocated to the research and development and regulatory registration of its in vitro diagnostic (IVD) product pipeline, the iteration and expansion of its metabolomics engineering platform, and the establishment and deepening of its marketing, sales, and service network. These efforts aim to accelerate Yinapu’s development and strategic layout in foundational technology platforms and diagnostic products for major diseases. Furthermore, leveraging its existing platforms, Yinapu will further advance the commercial translation of its existing achievements and secure regulatory approvals for IVD kits. Concurrently, the company will iterate on technology development targeting specific major diseases, screen and optimize novel biomarkers—including peptides and proteins—and their combinations to achieve clinical application.

Professor Qian Kun, Chief Scientist at InanoSpec, stated“Yinapu has been dedicated to the development of analytical methodologies for molecular omics and biomedical applications in major diseases. Driven by the practical needs of clinical application and exploration of biological mechanisms, we have developed a Molecular Omics Engineering Platform, which holds broad application prospects in the early in vitro diagnosis and monitoring of diseases. Addressing critical medical needs both domestically and internationally, we have initially established a series of criteria for the screening and identification of biomarkers and their combinations, thereby pioneering new clinical markets and application models. The future is already here; we look forward to China’s laboratory medicine industry nurturing a new generation of clinical technologies and methodologies that will exert a global impact.”

Ms. Wan Xinze, CEO of Inaspec, stated“Yinapu has remained dedicated to the original development and translational application of mass spectrometry-based testing technology platforms, building a health industry chain that spans clinical research, diagnostic reagents and equipment, third-party medical laboratory services, precision medicine, and health management, thereby establishing an initial closed-loop ecosystem. We are delighted that Yinapu has gained recognition from professional investors such as Wosheng Capital, as well as from industry partners and strategic investors. This support will enable us to deploy our proprietary nanochip analysis system in the early diagnosis and monitoring of major diseases, including cardiovascular and cerebrovascular disorders, metabolic diseases, and cancer, achieving breakthroughs in clinical diagnostic and therapeutic applications.”

Ms. Cao Zheng, Founding Partner of Wosheng Capital, stated“Benefiting from advancements in materials science, detection technologies, and data mining capabilities, a number of high-tech companies have emerged in China that specialize in multi-omics data mining and provide innovative, comprehensive translational medicine support for clinical practice. InaSpec stands out as a distinctive player among them. Led by Professor Qian Kun and a multidisciplinary team of scientists encompassing biology, chemistry, materials science, big data mining, and clinical medicine, InaSpec has developed omics analysis platforms and clinical diagnostic products with independent intellectual property rights. VCBeat is honored to have witnessed the team’s growth and served as an investor in the company’s first external financing round. Together with our co-investors, we will strive to help InaSpec expand into the clinical market and build it into a leading diagnostic platform company based on mass spectrometry technology, ultimately benefiting clinical practice.”

Dr. Ning Chenxi of Shicui Capital stated“It is a great honor to collaborate with Professor Qian Kun, Ms. Wan Xinze, and the Inaspec team. Professor Qian Kun and his team are globally recognized leaders in research areas such as solid-phase mass spectrometry applications and the discovery of metabolomic diagnostic biomarkers. Meanwhile, the company has successfully identified multiple small-molecule biomarker panels with significant commercial value and translated them into marketable products. The mining and exploration of emerging biomarkers represent one of the key trends in the global in vitro diagnostics industry, and we look forward to witnessing the rise of leading Chinese enterprises in this field.”

Dr. Xie Xiaolei, Chief Scientist at Shanghai Ruikang Biotechnology and Executive President of Shanghai Ruizhi Technology, stated“As mass spectrometry technology becomes more deeply integrated into clinical practice, there is a growing demand for compliance, standardization, and automation in clinical mass spectrometry. Meanwhile, the application of mass spectrometry in the development of novel disease biomarkers represents another exciting area of focus. Professor Qian Kun has been deeply engaged in this field for many years and is undoubtedly a leader in bridging medical engineering with clinical practice. We are delighted to establish a strategic partnership with Inano Mass Spec, leveraging our complementary strengths to create robust upstream-downstream synergy. We believe this collaboration will accelerate, deepen, and enhance the clinical application of mass spectrometry technology in China.”

Wosheng Investment, established in 2016, is a professional venture capital fund dedicated to investment opportunities in the biopharmaceutical sector. Technology-driven, it is committed to empowering leading scientists and entrepreneurs to achieve success. The firm has invested in numerous high-profile companies across China and the United States, leveraging its deep expertise in technologies such as gene editing and multi-omics. Its portfolio spans innovative drugs and therapies, diagnostic testing, and other areas, featuring companies founded by internationally renowned scientists and serial entrepreneurs, including Xunbaihui Biotechnology, Purui Benchmark, Lanyu Biotechnology, Shanghai Ruikang Biotechnology, Jialiang Medical, and Haihe Biotechnology. Wosheng Investment’s cornerstone investors include several powerful publicly listed pharmaceutical companies, all of which are domestic leaders in their respective niches.

Shicui Capital is committed to building a professional brand in early-stage healthcare investment, empowering outstanding entrepreneurs who master emerging technologies and possess industry consolidation capabilities to launch their ventures, thereby leading the innovation and transformation of China’s future healthcare industry.

Shanghai Ruikang Biotech is a high-tech enterprise specializing in the research and development, production, sales, and related technical services of medical diagnostic equipment and in vitro diagnostic (IVD) reagents. The company boasts standardized, large-scale, state-of-the-art manufacturing facilities and R&D laboratories, with R&D centers established in Shanghai, China, and Silicon Valley, USA. Its R&D, production, and management teams are led by Chinese and foreign PhD holders. The company has implemented a high-standard quality assurance system and obtained TÜV SÜD ISO 13485 certification. Its IVD technology platforms, particularly its clinical mass spectrometry platform, have gained extensive recognition from medical institutions and industry peers both domestically and internationally, and it has established strategic partnerships with renowned international enterprises and medical institutions. Shanghai Ruikang Biotech is committed to supporting the growth of China’s health industry with its leading technological capabilities and professional services.